SCHEMBL1100356

SCHEMBL1100356

Cc1c(N(C(C)C2CC2)S(=O)(=O)c2ccc(N3CCOCC3)cc2)sc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 4/20 0.43
TSHR P16473 2/20 0.40
PKM P14618 1/20 0.40
MMP8 P22894 3/20 0.38
MMP3 P08254 2/20 0.38
HTR2C P28335 1/20 0.37
HTR6 P50406 1/20 0.37
PRKDC P78527 1/20 0.37
PHOSPHO1 Q8TCT1 1/20 0.36
MAPT P10636 4/20 0.35
MAPK1 P28482 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
USP2 O75604 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099898 0.91 CNR2 (0.41) RORCHTR2CHTR6PHOSPHO1MAPT
SCHEMBL1098148 0.91 HTR2C (0.37) RORCHTR2CHTR6PSEN1PSEN2
SCHEMBL1100459 0.90 HTR6 (0.41) RORCHTR2CHTR6PSEN1PSEN2
SCHEMBL1099088 0.83 PSEN1 (0.39) MMP8MAPTSMN1; SMN2PSEN1PSEN2
SCHEMBL1099989 0.82 CYP2C9 (0.38) TSHRPRKDCMAPTMEN1KMT2A
SCHEMBL1099912 0.81 CNR2 (0.39) MAPTPSEN1PSEN2APH1BNCSTN
SCHEMBL1100358 0.79 TRPM8 (0.41) RORCTSHRPKMHTR2CHTR6
SCHEMBL1097813 0.76 PSEN1 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1098616 0.76 TRPM8 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1098475 0.75 TRPM8 (0.43) RORCTSHRPKMHTR6PHOSPHO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885TSHR 1373/4885PKM 1256/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885TSHR 1373/4885PKM 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.